Boston Scientific Corp (BSX)vsLivaNova PLC (LIVN)
BSX
Boston Scientific Corp
$48.55
-0.34%
HEALTHCARE · Cap: $70.87B
LIVN
LivaNova PLC
$72.36
-1.84%
HEALTHCARE · Cap: $4.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1338% more annual revenue ($20.61B vs $1.43B). BSX leads profitability with a 17.3% profit margin vs 7.5%. BSX appears more attractively valued with a PEG of 0.58. BSX earns a higher WallStSmart Score of 76/100 (B+).
BSX
Strong Buy76
out of 100
Grade: B+
LIVN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.4%
Fair Value
$37.35
Current Price
$48.55
$11.20 premium
Margin of Safety
+6.1%
Fair Value
$70.73
Current Price
$72.36
$1.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 100.0% YoY
Large-cap with strong market position
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 20.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Areas to Watch
No major concerns identified
7.5% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.
Bull Case : LIVN
The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.91 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
No major red flags identified for BSX, but monitor valuation.
Bear Case : LIVN
The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 40.5x leaves little room for execution misses.
Key Dynamics to Monitor
BSX profiles as a mature stock while LIVN is a value play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.88 — expect wider price swings.
LIVN is growing revenue faster at 14.3% — sustainability is the question.
BSX generates stronger free cash flow (171M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (76/100 vs 52/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?